Literature DB >> 10163413

Combination antiretroviral therapy in HIV infection. An economic perspective.

R D Moore1, J G Bartlett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 10163413     DOI： 10.2165/00019053-199610020-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  23 in total

1.  Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.

Authors:  J J Eron; S L Benoit; J Jemsek; R D MacArthur; J Santana; J B Quinn; D R Kuritzkes; M A Fallon; M Rubin
Journal:  N Engl J Med       Date:  1995-12-21       Impact factor: 91.245

2.  Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure.

Authors:  S D Paul; K M Kuntz; K A Eagle; M C Weinstein
Journal:  Arch Intern Med       Date:  1994-05-23

3.  A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

Authors:  J O Kahn; S W Lagakos; D D Richman; A Cross; C Pettinelli; S H Liou; M Brown; P A Volberding; C S Crumpacker; G Beall
Journal:  N Engl J Med       Date:  1992-08-27       Impact factor: 91.245

4.  Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.

Authors:  M A Fischl; R M Olson; S E Follansbee; J P Lalezari; D H Henry; P T Frame; S C Remick; M P Salgo; A H Lin; C Nauss-Karol; J Lieberman; W Soo
Journal:  Ann Intern Med       Date:  1993-05-15       Impact factor: 25.391

5.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

Authors:  W A O'Brien; P M Hartigan; D Martin; J Esinhart; A Hill; S Benoit; M Rubin; M S Simberkoff; J D Hamilton
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

6.  The hemodialysis prescription and cost effectiveness. Renal Physicians Association Working Committee on Clinical Guidelines.

Authors:  J C Hornberger
Journal:  J Am Soc Nephrol       Date:  1993-10       Impact factor: 10.121

7.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Authors:  A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey
Journal:  N Engl J Med       Date:  1996-04-18       Impact factor: 91.245

8.  New drugs for HIV infection.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1996-04-12       Impact factor: 1.909

9.  Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.

Authors:  H W Murray; K E Squires; W Weiss; S Sledz; H S Sacks; J Hassett; A Cross; R E Anderson; L M Dunkle
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245
View more
  22 in total

1.  Healthcare Economics in HIV.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

Review 2.  Cost effectiveness of combination HIV therapy: 3 years later.

Authors:  R D Moore
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

3.  Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection.

Authors:  P Sendi; A J Palmer; A Gafni; M Battegay
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  Economic models of antiretroviral therapy: searching for the optimal strategy.

Authors:  Fred J Hellinger
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Cost-effectiveness league tables: valuable guidance for decision makers?

Authors:  Josephine Mauskopf; Frans Rutten; Warren Schonfeld
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

6.  Ethical challenges posed by clinical progress in AIDS.

Authors:  R Bayer; J Stryker
Journal:  Am J Public Health       Date:  1997-10       Impact factor: 9.308

7.  A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.

Authors:  L Lacey; M Youle; P Trueman; S Staszewski; M Schrappe; M Behrens
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

8.  A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.

Authors:  L Lacey; J Mauskopf; R Lindrooth; S Pham; M Saag; W Sawyer
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

9.  Lamivudine reduces healthcare resource use when added to zidovudine-containing regimens in patients with HIV infection.

Authors:  L Lacey; M J Gill
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

10.  An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection. Canadian perspective.

Authors:  L Lacey; P K Hopkinson; J Montaner; F Leblanc; M J Gill
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.